We think the strategy to find more effective combination therapies in hematology and build a larger oncology and dermatology portfolio is solid, although we're waiting for key data before assuming the ...

Incyte shares (NASDAQ:INCY) saw their price target increased by TD Cowen from $86.00 to $88.00, with the firm maintaining a ...

Posting $162 million in fourth-quarter net sales, a 48% increase, and $508 million for the whole yeara 50% riseOpzelura ...

Earnings per Share (EPS) is expected to be $1.58, indicating a 49.1% increase year-over-year. Projected revenue is at $1.15 ...

Incyte reports mixed fourth-quarter 2024 results as earnings miss estimates while revenues beat the same. Jakafi and Opzelura drive year-over-year sales.

Jakafi is approved for use in patients with two types of cancers, myelofibrosis and polycythemia vera. Incyte forecast Jakafi sales in 2025 to be between $2.93 billion and $2.98 billion. Sales of ...

Incyte Corporation INCY is scheduled to report fourth-quarter and full-year 2024 results on Feb. 10, before the opening bell. The Zacks Consensus Estimate for the to-be-reported quarter’s revenues is ...

A panelist discusses how caregivers can support patients with polycythemia vera (PV) by helping track symptoms, managing medical appointments and recognizing warning signs that require physician ...

As evident by the MPN Research Foundation saying "Helping people with an MPN live a better quality of life as we work toward answers to the prevention, progression and a cure for polycythemia vera (PV ...

Aloe vera is a natural moisturizer, rich in antioxidants and anti-inflammatory properties. Many people find that aloe vera gel can hydrate and soothe eczema-damaged skin. Individuals may use ...

2018.08.022 6. Amé S, Barraco F, Ianotto JC, et al. Advances in management of primary myelofibrosis and polycythaemia vera: Implications in clinical practice. EJHaem. 2023;4(3):779-791.

Panelists discuss how health care providers can optimize quality-of-life and treatment outcomes for patients with myelofibrosis through comprehensive symptom management, shared decision-making, and ...